JAK2 and myelofibrosis: The JAK2 inhibitor, pacritinib, has shown promising application prospects in patients with advanced myelofibrosis who are resistant or intolerant to ruxolitinib (NCT04884191) [358], and is currently recruiting for a phase 3 trial involving patients with myelofibrosis and severe thrombocytopenia (NCT03165734).